News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CollaGenex Pharmaceuticals, Inc. (CGPI) Discontinues 40 mg Cohort of Phase II Dose-Finding Study of Incyclinide for the Treatment of Acne


5/7/2007 1:53:13 PM

NEWTOWN, Pa.--(BUSINESS WIRE)--CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that it has discontinued treatment of all enrolled patients participating in the 40 mg cohort of its Phase II dose-finding study of incyclinide for the treatment of acne. On May 2, 2007, CollaGenex announced that it had suspended enrollment of new patients in this cohort pending investigation of apparent significant photo-toxicity in one patient. Subsequently, the Company has learned of another case of apparent photo-toxicity and has discontinued treatment of all patients in this cohort. Following further investigation, CollaGenex will meet with the FDA to discuss the ongoing development program for incyclinide.

>>> Discuss This Story


Read at BioSpace.com


comments powered by Disqus
   
Acne

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES